Literature DB >> 17507492

DNA immunization using highly conserved murine cytomegalovirus genes encoding homologs of human cytomegalovirus UL54 (DNA polymerase) and UL105 (helicase) elicits strong CD8 T-cell responses and is protective against systemic challenge.

Christopher S Morello1, Laura A Kelley, Michael W Munks, Ann B Hill, Deborah H Spector.   

Abstract

Human cytomegalovirus (HCMV) establishes a lifelong infection with the potential for reinfection or viral transmission even in the presence of strong and diverse CD8 T-lymphocyte responses. This suggests that the CMVs skew the host T-cell response in order to favor viral persistence. In this study, we hypothesized that the essential, nonstructural proteins that are highly conserved among the CMVs may represent a novel class of T-cell targets for vaccine-mediated protection due to their requirements for expression and sequence stability, but that the observed subdominance of these antigens in the CMV-infected host results from the virus limiting the T-cell responses to otherwise-protective specificities. We found that DNA immunization of mice with the murine CMV (MCMV) homologs of HCMV DNA polymerase (M54) or helicase (M105) was protective against virus replication in the spleen following systemic challenge, with the protection level elicited by the M54 DNA being comparable to that of DNA expressing the immunodominant IE1 (pp89). Intracellular gamma interferon staining of CD8 T cells from mice immunized with either the M54 or M105 DNAs showed strong primary responses that recalled rapidly after viral challenge. M54- and M105-specific CD8 T cells were detected after the primary MCMV infection, but their levels were not consistently above the background level. The conserved, essential proteins of the CMVs thus represent a novel class of CD8 T-cell targets that may contribute to a successful HCMV vaccine strategy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507492      PMCID: PMC1933361          DOI: 10.1128/JVI.00633-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Identification of a K(d)-restricted antigenic peptide encoded by murine cytomegalovirus early gene M84.

Authors:  Rafaela Holtappels; Doris Thomas; Matthias J Reddehase
Journal:  J Gen Virol       Date:  2000-12       Impact factor: 3.891

Review 2.  Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance.

Authors:  Matthias J Reddehase
Journal:  Nat Rev Immunol       Date:  2002-11       Impact factor: 53.106

3.  Functional map of human cytomegalovirus AD169 defined by global mutational analysis.

Authors:  Dong Yu; Maria C Silva; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

4.  Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection.

Authors:  Michael W Munks; Kathy S Cho; Amelia K Pinto; Sophie Sierro; Paul Klenerman; Ann B Hill
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

5.  Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors.

Authors:  Hisashi Arase; Edward S Mocarski; Ann E Campbell; Ann B Hill; Lewis L Lanier
Journal:  Science       Date:  2002-04-11       Impact factor: 47.728

6.  Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65).

Authors:  C S Morello; L D Cranmer; D H Spector
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication.

Authors:  Christopher S Morello; Ming Ye; Deborah H Spector
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

8.  Strong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challenge.

Authors:  Ming Ye; Christopher S Morello; Deborah H Spector
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

9.  Functional profiling of a human cytomegalovirus genome.

Authors:  Walter Dunn; Cassie Chou; Hong Li; Rong Hai; David Patterson; Viktor Stolc; Hua Zhu; Fenyong Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-17       Impact factor: 11.205

10.  Cytomegalovirus misleads its host by priming of CD8 T cells specific for an epitope not presented in infected tissues.

Authors:  Rafaela Holtappels; Jürgen Podlech; Marcus-Folker Pahl-Seibert; Markus Jülch; Doris Thomas; Christian O Simon; Markus Wagner; Matthias J Reddehase
Journal:  J Exp Med       Date:  2003-12-29       Impact factor: 14.307

View more
  20 in total

1.  Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.

Authors:  Christopher S Morello; Michael S Levinson; Kimberly A Kraynyak; Deborah H Spector
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 2.  CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model.

Authors:  Rafaela Holtappels; Verena Böhm; Jürgen Podlech; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2008-03-15       Impact factor: 3.402

3.  25-Hydroxycholesterol activates the integrated stress response to reprogram transcription and translation in macrophages.

Authors:  Norihito Shibata; Aaron F Carlin; Nathanael J Spann; Kaoru Saijo; Christopher S Morello; Jeffrey G McDonald; Casey E Romanoski; Mano R Maurya; Minna U Kaikkonen; Michael T Lam; Andrea Crotti; Donna Reichart; Jesse N Fox; Oswald Quehenberger; Christian R H Raetz; M Cameron Sullards; Robert C Murphy; Alfred H Merrill; H Alex Brown; Edward A Dennis; Eoin Fahy; Shankar Subramaniam; Douglas R Cavener; Deborah H Spector; David W Russell; Christopher K Glass
Journal:  J Biol Chem       Date:  2013-11-04       Impact factor: 5.157

4.  Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine.

Authors:  Peter A Gillis; Nelmary Hernandez-Alvarado; Josephine S Gnanandarajah; Felix Wussow; Don J Diamond; Mark R Schleiss
Journal:  Vaccine       Date:  2014-05-20       Impact factor: 3.641

5.  Immune control in the absence of immunodominant epitopes: implications for immunotherapy of cytomegalovirus infection with antiviral CD8 T cells.

Authors:  Stefan Ebert; Niels A W Lemmermann; Doris Thomas; Angélique Renzaho; Matthias J Reddehase; Rafaela Holtappels
Journal:  Med Microbiol Immunol       Date:  2012-09-14       Impact factor: 3.402

6.  Identification of an atypical CD8 T cell epitope encoded by murine cytomegalovirus ORF-M54 gaining dominance after deletion of the immunodominant antiviral CD8 T cell specificities.

Authors:  Rafaela Holtappels; Niels A W Lemmermann; Doris Thomas; Angélique Renzaho; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2015-03-25       Impact factor: 3.402

7.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

8.  A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.

Authors:  Kristina Abel; Lisa Strelow; Yujuan Yue; Meghan K Eberhardt; Kimberli A Schmidt; Peter A Barry
Journal:  Vaccine       Date:  2008-08-27       Impact factor: 3.641

9.  Subdominant CD8 T-cell epitopes account for protection against cytomegalovirus independent of immunodomination.

Authors:  Rafaela Holtappels; Christian O Simon; Michael W Munks; Doris Thomas; Petra Deegen; Birgit Kühnapfel; Torsten Däubner; Simone F Emde; Jürgen Podlech; Natascha K A Grzimek; Silke A Oehrlein-Karpi; Ann B Hill; Matthias J Reddehase
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

Review 10.  Cytomegalovirus vaccine development.

Authors:  M R Schleiss
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.